Full Approval for Leukemia Immunotherapy
The FDA granted full approval to blinatumomab for certain patients with B-cell acute lymphoblastic leukemia The U.S. Food and...
The FDA granted full approval to blinatumomab for certain patients with B-cell acute lymphoblastic leukemia The U.S. Food and...
The FDA approved the PARP inhibitor talazoparib in combination with hormone therapy for metastatic prostate cancer The U.S. Food...
The FDA granted accelerated approval to another bispecific T-cell engager to treat certain B-cell lymphomas The U.S. Food and...
The FDA approved the DNA damage repair inhibitor olaparib, in combination with other therapies, for Castration-resistant or refractory prostate...
The FDA granted accelerated approval to the first bispecific T-cell engager to treat two types of B-cell lymphomas The...
The FDA has approved a new antibody-drug conjugate to treat two types of non-Hodgkin B-cell lymphomas The U.S. Food...
This is the first modified, donor cord blood–based stem cell therapy approved to reduce time to hematopoietic recovery and...
A targeted therapy is now available for more patients with advanced bladder cancers The U.S. Food and Drug Administration...
The FDA has approved the monoclonal antibody retifanlimab-dlwr for some patients with Merkel cell carcinoma. The U.S. Food and...
A targeted therapy regimen was approved to treat some children with brain cancer The U.S. Food and Drug Administration...